<DOC>
	<DOCNO>NCT01652157</DOCNO>
	<brief_summary>This long-term study cystic fibrosis patient participate Cystic Fibrosis Patient Registry ass occurrence risk factor rare bowel disorder call fibrosing colonopathy ( narrow large intestine ) . Patients follow regular clinical care visit 10-year period approach develop symptom fibrosing colonopathy collection use detailed information .</brief_summary>
	<brief_title>Long-term Study US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements Assess Narrowing Large Intestine Causing Adverse Intestinal Symptoms ( Fibrosing Colonopathy )</brief_title>
	<detailed_description>This prospective , observational , population-based cohort study US cystic fibrosis patient participate Cystic Fibrosis Patient Registry order ass incidence risk factor fibrosing colonopathy . Cystic fibrosis ( CF ) patient participate registry participate site , well new CF patient enrol registry site 2-year period , serve base study population ( estimate include 24,500-25,000 cystic fibrosis patient first patient encounter document registry participate site 31st July 2014 ) . Cystic fibrosis patient base study population follow regular clinical care visit , patient present 10-year period sign symptom suspect fibrosing colonopathy , base prospective definition , approach obtain study-specific informed consent collection additional data outside standard registry data collection form order augment surveillance . Data routinely collect via standard CF registry use determine exposure specific pancreatic enzyme replacement therapy ass potential risk factor outcome confirm fibrosing colonopathy . An independent adjudication panel utilized validate diagnosis fibrosing colonopathy base prospective case definition well decision rule . This harmonized protocol reflect equal sponsorship register Sponsor , AbbVie , also Collaborators , Aptalis Pharma Janssen Research &amp; Development , LLC .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>The inclusion criterion enrollment Base Study Population Diagnosed cystic fibrosis , Enrolled Cystic Fibrosis Patient Registry Receiving medical care Cystic Fibrosis Foundationaccredited care center provide data Cystic Fibrosis Patient Registry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prospective</keyword>
	<keyword>pancreatic insufficiency</keyword>
	<keyword>fibrosing colonopathy</keyword>
	<keyword>observational</keyword>
	<keyword>pancreatic enzyme replacement therapy</keyword>
</DOC>